Axel Hinke

13.4k citations
191 papers · 8.9k · 5 hit papers · h-index 41

Impact in

  • Oncology top 0.2%
    • Pancreatic and Hepatic Oncology Research
    • Colorectal Cancer Treatments and Studies
    • Viral-associated cancers and disorders
    • Lymphoma Diagnosis and Treatment

Papers in

    • Colorectal Cancer Treatments and Studies 44
    • Cancer Treatment and Pharmacology 23
    • HER2/EGFR in Cancer Research 13
    • Pancreatic and Hepatic Oncology Research 13
    • Gastric Cancer Management and Outcomes 19

Axel Hinke

182 papers receiving 8.6k citations

Axel Hinke's Hit Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial 2013 · 1.0k citations
1.0k0+6+13Years since publication4008001.2k

Peers

Axel Hinke
Comparison fields: 5 of 121
  • Oncology 4.8k
  • Pathology and Forensic Medicine 1.5k
  • Genetics 831
  • Pulmonary and Respiratory Medicine 2.3k
  • Cancer Research 966
Replace Lee S. Rosen with:
Lee S. Rosen United States
Christophe Massard France
Saul E. Rivkin United States
Helen X. Chen United States
A. Harstrick Germany
Christine Chevreau France
Sergei Tjulandin Russia
Cheolwon Suh South Korea
Igor Bondarenko United States
Viktor Grünwald Germany
Axel Hinke relative to Lee S. Rosen United States Lee S. Rosen's profile →
Citations per field
00.5×2.7×
Lee S. Rosen · 1×
Citations per year

Countries citing papers authored by Axel Hinke

Since Specialization
Citations

This map shows the geographic impact of Axel Hinke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Hinke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Hinke more than expected).

Fields of papers citing papers by Axel Hinke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Axel Hinke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Hinke. The network helps show where Axel Hinke may publish in the future.

Co-authors

The 25 scholars most cited alongside Axel Hinke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Axel Hinke Line = papers co-authored together Axel Hinke links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 191 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
Hit paper breakdown →
20131315
2
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Hit paper breakdown →
20131013
3
Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95
Hit paper breakdown →
2009616
4
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer
Hit paper breakdown →
2006552
5
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Hit paper breakdown →
2011439
6 2008348
7 2007219
8 2002185
9 2015178
10 2008156
11 2010135
12 2008124
13
Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas.
1994123
14 2009116
15 2015115
16 2020111
17 2007111
18 2009106
19 200795
20 200979

About Axel Hinke

Axel Hinke is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Cancer Research and Hematology, having authored 191 papers that have together received 8.9k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (44 papers), Cancer Treatment and Pharmacology (23 papers), Gastric Cancer Management and Outcomes (19 papers), Lymphoma Diagnosis and Treatment (16 papers), Multiple Myeloma Research and Treatments (14 papers), HER2/EGFR in Cancer Research (13 papers), Pancreatic and Hepatic Oncology Research (13 papers) and Breast Cancer Treatment Studies (12 papers). The work is most often cited by research in Oncology (4.8k citations), Pathology and Forensic Medicine (1.5k citations), Genetics (831 citations), Pulmonary and Respiratory Medicine (2.3k citations) and Cancer Research (966 citations). Axel Hinke has collaborated with scholars based in Germany, United States and Austria. Frequent co-authors include Volker Heinemann, Hanno Riess, Andreas Hochhaus, Helmut Oettle, Klaus Gellert, Jörg Fahlke, P. Neuhaus, C. Zülke, Marianne Sinn and Marco Niedergethmann. Their work appears in journals such as Journal of Clinical Oncology, Blood, Annals of Oncology, BMC Cancer and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact